Galectin Therapeutics (GALT) Enterprise Value (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Enterprise Value of -$14.1 million for Q1 2026, down 89.89% year-over-year from -$139.6 million in Q1 2025, and up 20.37% quarter-over-quarter from -$17.7 million in Q4 2025.
Galectin Therapeutics (GALT) Enterprise Value (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$14.1 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 89.89% year-over-year to -$14.1 million; the TTM figure through Mar 2026 stood at -$14.1 million (down 89.89% YoY), while the FY2025 annual figure was -$17.7 million, down 17.2% from the prior year.
- Enterprise Value for Q1 2026 stood at -$14.1 million, up from -$17.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$7.4 million in Q1 2025, with the low at -$31.6 million in Q1 2022.
- The 5-year median for Enterprise Value is -$18.0 million (2023), against an average of -$19.3 million.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value jumped 68.45% in 2025, then plunged 89.89% in 2026.
- Galectin Therapeutics' Enterprise Value stood at -$18.6 million in 2022, then slumped by 38.02% to -$25.7 million in 2023, then surged by 41.08% to -$15.1 million in 2024, then slipped by 17.2% to -$17.7 million in 2025, then climbed by 20.37% to -$14.1 million in 2026.
- Business Quant data shows GALT's Enterprise Value at -$14.1 million in Q1 2026, -$17.7 million in Q4 2025, and -$11.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | -14.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.11 Mn |
| Dec 31, 2025 | -17.72 Mn |
| Sep 30, 2025 | -11.53 Mn |
| Jun 30, 2025 | -13.77 Mn |
| Mar 31, 2025 | -7.43 Mn |
| Dec 31, 2024 | -15.12 Mn |
| Sep 30, 2024 | -27.06 Mn |
| Jun 30, 2024 | -25.60 Mn |
| Mar 31, 2024 | -23.56 Mn |
| Dec 31, 2023 | -25.66 Mn |
| Sep 30, 2023 | -20.36 Mn |
| Jun 30, 2023 | -17.97 Mn |
| Mar 31, 2023 | -17.80 Mn |
| Dec 31, 2022 | -18.59 Mn |
| Sep 30, 2022 | -15.83 Mn |
| Jun 30, 2022 | -24.18 Mn |
| Mar 31, 2022 | -31.61 Mn |
| Sep 30, 2021 | -36.60 Mn |
| Jun 30, 2021 | -31.60 Mn |
| Mar 31, 2021 | -20.76 Mn |